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Abstract
Background: Type 2 diabetes often displays hyperlipidemia. We examined palmitate effects on pancreatic islet function in
relation to FFA receptor GPR40, NO generation, insulin release, and the PPARc agonistic thiazolidinedione, rosiglitazone.
Principal Findings: Rosiglitazone suppressed acute palmitate-stimulated GPR40-transduced PI hydrolysis in HEK293 cells
and insulin release from MIN6c cells and mouse islets. Culturing islets 24 h with palmitate at 5 mmol/l glucose induced b-
cell iNOS expression as revealed by confocal microscopy and increased the activities of ncNOS and iNOS associated with
suppression of glucose-stimulated insulin response. Rosiglitazone reversed these effects. The expression of iNOS after high-
glucose culturing was unaffected by rosiglitazone. Downregulation of GPR40 by antisense treatment abrogated GPR40
expression and suppressed palmitate-induced iNOS activity and insulin release.
Conclusion: We conclude that, in addition to mediating acute FFA-stimulated insulin release, GPR40 is an important
regulator of iNOS expression and dysfunctional insulin release during long-term exposure to FFA. The adverse effects of
palmitate were counteracted by rosiglitazone at GPR40, suggesting that thiazolidinediones are beneficial for b-cell function
in hyperlipidemic type 2 diabetes.
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Introduction
The nutrients glucose and free fatty acids (FFA) are known to
have a great impact on the function of pancreatic b-cells [1,2,3].
Although glucose is the major stimulus for insulin secretion, its
effects are highly modulated by FFA. Insulin secretion might thus
be acutely amplified or chronically inhibited by FFA-derived
signals [1,2,3]. Although interaction between FFA and b-cells
plays an important role in insulin secretion, the intimate targets
responsible for FFA actions on b-cells are under debate and FFA
and cytokines have been claimed to induce b-cell apoptosis by
different mechanisms [3]. The acute stimulatory effects have been
linked to the action of long chain acyl-CoA molecules on a variety
of metabolic sites involved in the insulin secretory pathways
[1,2,3]. This concept has recently been challenged since the
stimulatory action of FFA on insulin secretion, at least in part, was
shown to be mediated through a membrane-bound FFA receptor,
the G protein-coupled receptor 40 (GPR40) [4,5,6]. Notably, the
peroxisome proliferator-activated receptor c (PPARc), a member
of the nuclear receptor superfamily, is involved in islet FFA
metabolism. PPARc is modulated by e.g. prostaglandin J2,
leukotrine B4 and by a number of recently developed synthetic
agents (thiazolidinediones) like rosiglitazone (ROZ) [7,8,9,10].
Since FFA are involved in developing insulin resistance, synthetic
agonists of PPARc have been used clinically to improve glucose
tolerance by enhancing insulin sensitivity of adipocytes to suppress
lipolysis thus reducing the metabolic burden to liver and muscle
that in turn improves glucose homeostasis [7,8,9,10].
Since we have shown that long-term intralipid infusion in rats is
accompanied by expression of inducible nitric oxide synthase
(iNOS) in pancreatic islets [11,12,13], and since excessive NO
generation derived from both iNOS and neuronal constitutive
NOS (ncNOS) seems involved in impairment of glucose-
stimulated insulin release and b-cell dysfunction [14,15,16,17,
18,19,20], we found it essential to explore in more detail the effects
of FFA on pancreatic islet function. Hence the aim of the present
investigation was to study both acute and especially long-term
effects of palmitate and its interaction with the PPARc agonist
ROZ on the activities of islet NOS isoenzymes in relation to
GPR40 and insulin secretion and thus to further elucidate whether
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2182the thiazolidinedione drugs would be of possible therapeutic value
for the function of the b-cell in dyslipidemic type 2 diabetes.
Results
Acute effects of palmitate and ROZ on PI hydrolysis in
GPR40-transfected HEK293 cells and their interaction
with PI hydrolysis and insulin release in MIN6c4 cells, as
well as palmitate-induced effects on islet NOS activities
and effects of ROZ and diazoxide on insulin release from
isolated islets
We first tested the acute action-interaction of palmitate in relation
to ROZ on PI hydrolysis in HEK293 cells transiently expressed with
mouse GPR40. HEK293 cells do not express endogenous GPR40
[21] and is well suited to explore the immediate response to GPR40
ligands after transient expression of the receptor. Fig. 1A shows that
PI hydrolysis after 30 min incubation of GPR40-transfected
HEK293 cells in presence of 1 mmol/l palmitate is highly increased
compared with nontransfected controls and that ROZ by itself has a
significant agonistic action. Fig. 1B, on the other hand, shows that
ROZ has an inhibitory action on the palmitate-stimulated PI
hydrolysis in transfected cells.
Next we used MIN6c4 insulinoma cells, known to endogenously
express GPR40 [21] to study whether ROZ interacts with the
reported FFA-stimulated activation of PLC via GPR40 in insulin-
producing cells. MIN6c4 cells were challenged with palmitate for
30 min in absence or presence of ROZ, and PI hydrolysis was
analyzed. Fig. 1C and D, shows that palmitate-stimulated PI
hydrolysis and insulin release in fact were dose-dependently
suppressed by ROZ.
To test possible involvement of NOS enzyme activities in
relation to palmitate-induced insulin release in acute experiments
with primary b-cells, freshly isolated islets were incubated for
60 min. Fig. 1E shows basal and acute palmitate-modulated NOS
activities and insulin release at 5 mmol/l glucose. ncNOS activity
was increased but iNOS was not detectable. Notably, a restraining
action of palmitate-induced insulin release through ncNOS-
derived NO was revealed by showing a greatly amplified insulin
release (Fig. 1F) in the presence of the ncNOS inhibitor L-
NAME. Hence ncNOS-generated NO abrogated a major part of
the palmitate-induced insulin release. Finally, Fig. 1G shows that
the acute amplifying effect of palmitate on glucose-stimulated
insulin release was greatly suppressed by ROZ. In comparison the
KATP-channel opener diazoxide was even more efficient (Fig. 1G).
A similar, although not identical pattern was seen for palmitate-
induced insulin release at low glucose (Fig. 1G).
Pattern of insulin secretion and islet insulin content
during long-term culturing with palmitate or glucose in
the absence or presence of ROZ or diazoxide
Long-term experiments with palmitate or glucose were
performed to study effects of ROZ or for comparison, diazoxide,
on insulin secretion and insulin content in islets cultured for 24 h
in absence or presence of either agent. Fig. 2 shows that both
palmitate and a high concentration of glucose (20 mmol/l) not
only increased insulin release into the culture medium (Fig. 2A)
but also slightly increased islet insulin content (Fig. 2B). ROZ
suppressed insulin secretion during culture with palmitate, while
slightly amplifying insulin secretion in presence of high glucose
(Fig. 2A). Diazoxide suppressed insulin secretion during culture
with high glucose and only marginally inhibited it in presence of
palmitate. ROZ or diazoxide did not affect islet insulin content
(Fig. 2B).
Effects of islet culturing with palmitate in presence and
absence of ROZ or diazoxide on islet NOS activities and
glucose-stimulated insulin secretion
Islets cultured for 24 h at 5 mmol/l glucose (basal) or 5 mmol/l
glucose+palmitate in absence or presence of ROZ or diazoxide
were analyzed for ncNOS and iNOS activities. Fig. 3A shows that
palmitate did not only induce a marked increase in ncNOS activity
but also an exclusive activity of iNOS. The stimulatory effect of
palmitate on ncNOS and iNOS activities was markedly attenuated
when ROZ was present during the culture period. Diazoxide only
slightly influenced the stimulatory effect of palmitate on NOS
activities (Fig. 3A).
A major part of the cultured islets from the same culturing
batches were thereafter washed, preincubated in 1 mmol/l glucose
for 30 min and incubated at 1 or 20 mmol/l glucose for 60 min.
Fig. 3B illustrates that insulin release was slightly increased at low
glucose when islets had been cultured with palmitate but not when
ROZ or diazoxide was present. Conversely, glucose-stimulated
insulin release was markedly attenuated after culturing with
palmitate. This suppressive effect by palmitate was completely
reversed when ROZ was present during the culture period but
only slightly so when diazoxide was present.
Confocal microscopy
The cellular distribution of iNOS protein was examined with
confocal microscopy. Fig. 4 shows that after culture with
palmitate (D–F) or high glucose (J–L) iNOS immunoreactivity
was expressed in most islet cells, which also displayed insulin
immunoreactivity. No iNOS immunoreactivity was detected in
islets cultured at basal glucose (A–C). Addition of ROZ to culture
medium suppressed palmitate-induced iNOS expression in b-cells
(G–I), whereas glucose-induced expression of iNOS induced by
high glucose was not affected (M–O).
Suppression of GPR40 by antisense M40 in cultured
pancreatic islets abrogated palmitate-induced expression
of iNOS and suppressed the activities of ncNOS and iNOS
as well as insulin secretion
To explore whether GPR40 is involved in both palmitate-
induced expression of islet iNOS and palmitate stimulation of
insulin release during culture with 5 mmol/l glucose we used an
antisense (M40) targeting the sequence important for the GPR40
transcript in islets. After culturing, islets were thoroughly washed
and processed for the measurement of ncNOS and iNOS
activities, insulin release into medium, and detection of iNOS
protein. Fig. 5A shows abrogation of palmitate-induced iNOS
activity, reduction of ncNOS activity, and inhibition of insulin
secretion into culture medium in M40-treated islets. Confocal
microscopy showed that palmitate-induced iNOS expression was
colocalized with GPR40 (Fig. 5B, A–C) and abrogated together
with GPR40 expression after M40 treatment (D–F). The
colocalization of insulin, GPR40 and iNOS is shown in single b-
cells (Fig. 5C) (A–D). The loss of GPR40 and iNOS proteins after
M40 treatment is also shown (E–H).
Discussion
It is known that FFA are positive modulators of insulin secretion
in short-time perspective but become toxic to b-cells when
chronically present in elevated levels (lipotoxicity) [1,2,3,8,9,10].
Thus prolonged exposure of b-cells to FFA leads to increased basal
but suppressed glucose-stimulated insulin secretion [1,2,8,9,10].
Since many type 2 diabetic patients exhibit elevated plasma levels
FFA, GPR40 and Insulin Release
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2182Figure 1. Short-time effects of palmitate and rosiglitazone (ROZ) on phosphatidyl inositol (PI) hydrolysis, in HEK293 and MIN6c4
cells, insulin release in MIN6c4 cells as well as NO production and insulin release in isolated islets. (A) PI hydrolysis in nontransfected
and GPR40-transfected HEK293 cells in response to palmitate (1 mmol/l) and ROZ (50 mmol/l) (n=8–12) and (B); dose-dependent effect of ROZ on
palmitate-induced PI hydrolysis (n=8-12). (C, D) PI hydrolysis and insulin release in MIN6c4 cells in response to palmitate (1 mmol/l)6ROZ at
different concentrations (n=6). (E) NO production from neuronal constitutive nitric oxide synthase (ncNOS), inducible NOS (iNOS) and total NOS as
well as insulin release in response to palmitate (1 mmol/l) after 60 min incubation of freshly isolated mouse islets at 5 mmol/l glucose (5G) (n=4). (F)
Effect of the NOS inhibitor L-NAME on insulin release induced by palmitate (1 mmol/l) in the presence of 5 mmol/l glucose (n=8). (G) Effects of
palmitate6ROZ or diazoxide on insulin release from freshly isolated mouse islets incubated at low (1 mmol/l) or high (20 mmol/l) glucose for 60 min.
The concentrations of the different test agent were; palmitate (1 mmol/l), ROZ (1 mmol/l), diazoxide (dz) (250 mmol/l) (n=8-12). Values are
mean6s.e.m for. ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0002182.g001
FFA, GPR40 and Insulin Release
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for the deleterious action of long-term elevation of FFA on b-cells
and glucose-induced insulin release would be highly important to
elucidate. The present results favor the view that the adverse effects
of chronic exposure to FFA is exerted mainly through the newly
discovered FFA receptor GPR40byinducing expression and activity
of b-cell iNOS, a highly increased NO generation, and suppression
of glucose-stimulated insulin release. Moreover, we show that this
deleterious action of FFA on the b-cells is counteracted by the
thiazolidinedione drug ROZ, which inhibits GPR40 transduction
mechanisms and thus abrogates iNOS expression and in addition
restores glucose-stimulated insulin release.
In our initial acute experiments we verified the reported acute
activation of PLC and PI hydrolysis by GPR40-mediated
Figure 2. Insulin secretion and islet insulin content after
culturing with palmitate or high glucose. Insulin secretion into
culture medium (A) and islet insulin content (B) from isolated islets
cultured for 24 h at a basal glucose concentration of 5 mmol/l (5G),
5G+palmitate (1 mmol/l) (Palm), 5G+palmitate+rosiglitazone (1 mmol/l)
(Palm+ROZ) or 5G+palmitate+diazoxide (250 mmol/l) (Palm+Dz) as well
as at high glucose concentration (20 mmol/l) (20G), 20G+rosiglitazone
(1 mmol/l) (20G+ROZ) or 20G+diazoxide (250 mmol/l) (20G+Dz). The
means6s.e.m for 10-12 batches of islets in each group are shown.
Asterisks denote probability level of random difference. * P,0.05;
***P,0.001.
doi:10.1371/journal.pone.0002182.g002
Figure 3. Islet NO generation from neuronal constitutive nitric
oxide synthase (ncNOS), inducible NOS (iNOS), and total NOS
after culturing with palmitate for 24 h as well as insulin release
at basal and high glucose after a subsequent incubation. (A)
Total NOS as well as ncNOS and iNOS activities in isolated islets cultured
at a basal glucose concentration of 5 mmol/l (5G), 5G+palmitate
(1 mmol/l) (Palm), 5G+palmitate+rosiglitazone (1 mmol/l) (Palm+ROZ) or
5G+palmitate+diazoxide (250 mmol/l) (Palm+Dz) (n=8). (B) Insulin
release at low (1 mmol/l) glucose or stimulated by high (20 mmol/l)
glucose from islets incubated for 60 min after culturing and washing.
The means6s.e.m for 10-12 batches of islets in each group are shown.
Asterisks denote probability level of random difference. * P,0.05;
** P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0002182.g003
FFA, GPR40 and Insulin Release
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by palmitate was inhibited by ROZ in HEK293 cells transiently
transfected with GPR40 and in MIN6c4 insulin-producing cells
with endogenously expressed GPR40, where ROZ was found to
suppress palmitate-stimulated insulin release. These results appear
to contradict earlier reports [21] suggesting ROZ to be a GPR40
agonist. However, the previous reports [21,22] were based on
recombinant cell systems with high receptor densities. The most
likely explanation is that ROZ is a partial agonist with high affinity
and relatively low efficacy, and thus being more dependent on
receptor density. We show now that ROZ served as a potent
GPR40 inhibitor of palmitate-induced PI hydrolysis and that
ROZ dose-dependently suppressed palmitate-stimulated PI hy-
drolysis in GPR40-transfected HEK293 cells as well as PI
hydrolysis and insulin release in MIN6c4 cells. Moreover, we
show that acute palmitate-stimulating effects on insulin release
Figure 4. Confocal microscopy of mouse islets. Isolated islets were cultured for 24 h at a basal glucose concentration of 5 mmol/l (A–C);
5G+palmitate (1 mmol/l) (D–F); 5G+palmitate+rosiglitazone (1 mmol/l) (G–I) or 20G (J–L) and 20G+rosiglitazone (1 mmol/l) (M-O). After the culturing
period the islets were double-immunolabelled for insulin (appears as red) (A, D, G, J and M) and iNOS (appears as green) (B, E, H, K and N) and
analyzed by confocal microscopy. Co-localization of insulin/iNOS is seen as a yellowish fluorescence (C, F, I, L and O). Fluorescence intensity data of
iNOS (green) were normalized to 100% as measured in E (5G+palmitate) and gave the following results (n=12). B=1.5060.75; E=100.662.52;
H=4.3361.50; K=99.062.96; N=106.163.22.
doi:10.1371/journal.pone.0002182.g004
FFA, GPR40 and Insulin Release
PLoS ONE | www.plosone.org 5 May 2008 | Volume 3 | Issue 5 | e2182Figure 5. Islet NOS activities, insulin secretion, and expression of GPR40 and iNOS after treatment with palmitate and GPR40
antisense. Isolated islets were pretreated for 24 h with either the M40 antisense morpholino or a non-specific random sequence morpholino
(control). The islets were incubated for 30 min in absence or presence of palmitate and then cultured with palmitate6M40 for a further 24 h. (A) M40
caused a marked suppression of palmitate-induced iNOS and ncNOS activities as well as a reduced insulin release (black bars). The results from the
control morpholino are indicated by white bars. Values are mean6s.e.m for 4 different experiments performed at different occasions. ** p,0.01; ***
p,0.001. (B) Expression of GPR40 (green) and iNOS (red) in islets cultured with palmitate (A-C) or palmitate+M40 (D-F). A and D=GPR40; B and
E=iNOS, C and F=overlay. Bar indicates 5 mm. (C) Immunostaining and confocal images of formaldehyde-fixed b-cells. The expression pattern of
insulin (red), GPR40 (green) and iNOS (yellow) from dispersed b-cells cultured with palmitate is shown. A=insulin, B=GPR40, C=iNOS and
D=overlay. E–H show absence of expression of GPR40 (F) and iNOS (G) after M40 treatment. E=insulin, H=overlay. Bar indicates 5 mm.
doi:10.1371/journal.pone.0002182.g005
FFA, GPR40 and Insulin Release
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the inhibition of which by the ncNOS inhibitor L-NAME resulted
in marked amplification of palmitate-induced insulin response.
This acute restraining action by ncNOS-derived NO on palmitate-
induced insulin release thus agrees with our previous observations
on acute glucose-induced insulin release [17,18,19,20].
We have postulated and presented suggestive data showing that
ncNOS-derived NO is rapidly stimulated by glucose and exerts an
acute negative feedback action on glucose-induced insulin release
[18]. This effect is elicited within minutes and probably involved in
creating the nadir separating first and second phase insulin
response. This is in accordance with the notion that part of the
ncNOS protein is confined to the insulin secretory granules [23].
We also found that the Ca
2+/calmodulin-dependent ncNOS
activity was markedly inhibited by the ATP-sensitive K
+ channel
opener diazoxide [18]. In contrast to the rapid action of glucose on
ncNOS activity, there was no effect by glucose on iNOS
expression until after ,1 h of exposure to high glucose in vitro
and in vivo [18,20]. The Ca
2+/calmodulin-independent iNOS
activity was not inhibited by diazoxide [18] and iNOS-derived NO
reportedly exerts cytotoxic and apoptotic effects in b-cells [16,24].
Importantly, however, in contrast to glucose, the present data
show that acute exposure to palmitate did not induce iNOS
activity after short-time (,1 h) incubation suggesting distinct time-
dependent mechanisms for palmitate vs glucose in iNOS induction
and activity. Finally, the acute amplifying effect by palmitate on
glucose-stimulated insulin release, which reportedly is linked to
activation of GPR40 [5,6,25], we now found to be suppressed by
ROZ, while the glucose-stimulated part of the release process was
unaffected.
We have shown earlier that glucose-stimulated insulin release is
disrupted in islets from long-term lipid-infused rats whose islets
displayed increased NO production due to induction of iNOS
expression [11,12,13]. Since we repeatedly found [17,18,19,20]
that increased islet NO production in presence of high glucose
inhibits insulin release and most likely is taking part in a process of
glucotoxicity we are now inclined to ascribe increased iNOS-
derived NO in islets cultured with palmitate as an important factor
in FFA-induced lipotoxicity. Although there seems to be distinct
differences in induction and prevention of iNOS expression and
activity elicited by glucose vs FFA, increased islet iNOS-derived
NO production might be a common denominator in both
glucotoxicity and lipotoxicity.
Since ROZ, although debated, has been suggested to be an
alternative drug in long-term therapy of type 2 diabetes we were
particularly interested in the action of ROZ on long-term effects of
FFA, as represented by palmitate, on islet activation of ncNOS
and iNOS in relation to glucose-stimulated insulin release. After
culturing with palmitate at basal glucose concentration insulin
release into medium was enhanced 3-fold compared with basal
glucose alone, while islets cultured at high glucose displayed almost
7-fold increase in insulin. Diazoxide abrogated this glucose-
induced insulin response, whereas palmitate-induced insulin
release was only slightly reduced, suggesting K
+
ATP channel-
dependent Ca
2+ influx mechanisms over time being less important
for palmitate-stimulated insulin secretion during this long-term
culturing compared with acute effects and possibly more
influenced by intracellular Ca
2+ perturbations [25]. Importantly,
during culturing ROZ markedly reduced palmitate-induced but
slightly increased glucose-induced insulin secretion into medium.
These differences did not depend on islet insulin content, but are
likely related to partially differential effects on insulin secretory
mechanisms. PPARc receptors in b-cells show reportedly a
comparatively low expression [8] and hence other effects than
directly on these receptors might also play a role in the effects of
ROZ on insulin release as previously have been suggested [26].
Studies in models of type 2 diabetes have shown that thiazolidi-
nediones enhance b-cell function by mobilizing fat out of the cells
[27]. Moreover, it was very recently shown [28] that toxic
accumulation of cholesterol in b-cells and associated defects in
insulin release could be restored by ROZ through activation of the
cholesterol efflux transporter Abca 1, which is upregulated by
PPARc activation. Hence, thiazolidinediones exert diverse
beneficial effects on b-cell function as recently has been extensively
discussed [9]. Now we show that islets cultured with palmitate
displayed marked expression and activity of b-cell iNOS, increased
ncNOS activity and a greatly reduced insulin response following a
60 min glucose challenge. After culturing with palmitate+ROZ,
however, the increased NO production was abrogated and
glucose-stimulated insulin release restored to normal suggesting
that ROZ has a direct inhibitory effect on b-cell GPR40.
Conversely, after culturing in high glucose+ROZ confocal
microscopy showed no effect by ROZ on b-cell iNOS expression.
These findings suggest, but do not definitely prove, that iNOS
expression and activity in b-cells is regulated through different or
partially different mechanisms after long-term exposure to
palmitate vs glucose. It should be noted that when ROZ was
replaced by diazoxide during palmitate culturing iNOS activity
was unaffected and ncNOS activity and glucose-stimulated insulin
release were less suppressed than after palmitate+ROZ. Attenu-
ation of insulin release by KATP channel openers like diazoxide is
ascribed to b-cell hyperpolarization, thereby providing b-cell rest.
Notably, our present data suggest that such a protective effect on
glucose-stimulated insulin secretion after diazoxide treatment [29]
is not operating when high glucose is replaced by palmitate.
Hence, although the preserving effect by diazoxide on glucose-
stimulated insulin release is reportedly beneficial [29], our present
data suggest that this ‘‘resting’’ effect is less important in presence
of enhanced levels of FFA (palmitate).
The present data favor the idea that excessive and longstanding
generation of NO derived from iNOS is an important player in
FFA-induced b-cell dysfunction after long-term culturing. This is
accordance with previous data obtained in isolated islets from
prediabetic Zucker diabetic fatty rats [30]. In contrast Cnop et al
[31] using isolated b-cells from normal rats did not detect any
iNOS mRNA expression or nitrite production in their FFA
experiments. However, Cnop et al did not measure the expression
and activity of iNOS protein. It is known that a great deal of
endogenously generated NO is trapped within the cell by e.g. S-
nitrosylation [32] and thus nitrite production into the incubation
medium might not truly mirror the intracellular situation.
Interestingly a very recent report [33] showed that both (60 min)
and long-time culturing (20 h) of rat islets with the thiazolidine-
dione troglitazone stimulated AMP-activated protein kinase
(AMPK) activity, which was associated with a decrease of
glucose-stimulated insulin release after short-time and an increase
after long-time treatment. Although the experimental conditions in
their study were not strictly comparable to our study these data
show that AMPK might be involved in the thiazolidinedione
action on the b-cell. In another study with isolated b-cells [34]
FFA-induced cytotoxicity was found not to be decreased but
instead increased after treatment with troglitazone. Since the
experimental conditions in that study was different from ours,
especially with regard to the use of isolated b-cells instead of islets,
the data are not comparable. Notably, however, isolated islet b-
cells lack the presence of islet glucagon and glucagon-induced
stimulation of b-cell adenylate cyclase is expected to suppress
iNOS expression and activity [12,13,20].
FFA, GPR40 and Insulin Release
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GPR40 in the long-term action of palmitate to induce iNOS
expression and influence palmitate-stimulated insulin release. It
has recently been suggested that GPR40 is necessary but not
sufficient for FFA stimulation of insulin secretion in vivo [35].
However, these results are at variance with another recent study
[6] and because the data of these experimental studies were widely
different further studies are needed to finally elucidate this issue.
Our results suggest that knock-down of GPR40 suppressed both
palmitate-induced activity of iNOS and insulin release. Confocal
microscopy confirmed the antisense inhibition of both GPR40 and
iNOS expression in the b-cells. Hence, GPR40 is a major
regulator of iNOS expression and insulin release during long-term
exposure to palmitate. The palmitate-induced NO generation and
associated suppression of glucose-stimulated insulin release is
counteracted by ROZ at the GPR40 receptor, and thus, ROZ and
other thiazolidinedione drugs might be beneficial for b-cell
function in hyperlipidemic type 2 diabetes..
Materials and Methods
Animals
Female mice of the NMRI strain (B&K, Sollentuna, Sweden)
weighing 25–30 g were used. They were given a standard pellet
diet (B&K) and tap water ad libitum throughout the experiments.
All animals used for preparation of pancreatic islets were killed by
cervical dislocation. The experimental procedures were approved
by the Ethical Committee for Animal Research at University of
Lund; Sweden.
Drugs and chemicals
Collagenase (CLS 4) was from Sigma Chemical Co (St Louis,
MO, USA), HRP-conjugated goat anti-rabbit IgG was from Pierce
Biotechnology, Rockford, IL, USA. Cy2-conjugated anti-mouse
IgG and Cy5-conjugated anti-guinea pig IgG were from Jackson
Immunoresearch Laboratories Inc, West Grove, PA, USA.
Guinea pig-raised anti-insulin antibody was from Eurodiagnostica,
Malmo ¨, Sweden. Fatty acid free bovine serum albumin (BSA) was
from Boehringer Mannheim, Germany. ROZ was a kind gift from
Glaxo Smith-Kline, London, UK. N
G-nitro-L-arginine methyl
ester (L-NAME) was from Sigma. The insulin radioimmunoassay
kits were from Diagnostika, Falkenberg, Sweden. All other
chemicals were from Merck AG, (Darmstadt, Germany) or Sigma.
Islet culturing and insulin secretion
Preparation of pancreatic islets from the mouse was performed
by retrograde injection of a collagenase solution via the bile-
pancreatic duct [14]. Islets were then isolated and hand-picked
under a stereomicroscope at room temperature. After washing the
islets were either used for short-term experiments and incubated as
described previously [12] or used for culturing experiments. The
islets were thereby cultured for 24 h in RPMI 1640 (SVA,
Uppsala, Sweden) supplemented with 10% calf serum, 100 U/ml
penicillin and 10 mg/ml streptomycin in the presence or absence
of different test agents as indicated in the legends. After culturing
the islets were preincubated for 30 min at 37uC in Krebs-Ringer
bicarbonate buffer, pH 7.4, supplemented with 10 mmol/l
HEPES, 0.1% BSA and 1.0 mmol/l glucose. After preincubation
the buffer was changed and the islets were incubated at 1 or
20 mmol/l glucose for 60 min at 37uC unless otherwise stated.
Each incubation vial contained 12 islets in 1.0 ml of buffer solution
and was gassed with 95% O2-5% CO2 to obtain constant pH and
oxygenation. All incubations were performed in an incubation box
at 30 cycles/min. An aliquot of the medium was removed
immediately after incubation and frozen for the subsequent assay
of insulin. Palmitate was dissolved in ethanol (95%) with
subsequent addition of stoichiometric amounts of NaOH. The
stock solution was carefully evaporated under nitrogen gas. The
dried residue was dissolved in water and thereafter heated to
create a hot soap. The palmitate solution was stirred and fatty acid
free BSA was added (10% w/v) and the pH was adjusted to 7.4
with NaOH. The solution was aliquoted and stored at –20 C. At
the time of experiments, the stock solution of palmitate-BSA was
diluted 1:10 in the KRB or RPMI 1640 buffer to achieve the
desired concentration of palmitate. All components of the buffer
used in the experiments were prepared to be 10% more
concentrated to adjust for the addition of palmitate-BSA stock
solution. Under control conditions, BSA (1% w/v) was always
included. The procedure has been described in detail previously
[36]. In some experiments the islets were cultured for 24 h in
RPMI 1640 (SVA, Uppsala, Sweden) supplemented with 10% calf
serum, 100 U/ml penicillin and 10 mg/ml streptomycin in the
presence or absence of either a mouse GPR40 (mGPR40) specific
antisense or a nonsense morpholino oligonucleotide (Gene-Tools)
at a concentration of 1.4 mM [5].
Assay of islet NOS activities
After a culture period of 24 h, aliquots of the medium were
removed for determination of insulin whereafter the islets were
washed and collected in 200 ml buffer, containing 20 mmol/l
HEPES, 0.5 mmol/l EDTA and 1/l mmol/l DL-dithiothreitol, and
thereafter stored at 220uC. On the day of the assay, the islets were
sonicated on ice and the buffer solution was enriched with
0.45 mmol/l CaCl2, 2 mmol l/l NADPH, 25 U/ml calmodulin,
and 0.2 mmol/l L-arginine. For the determination of iNOS activity
both Ca
2+ and calmodulin were omitted. The homogenate was
incubated at 37uC under constant air bubbling with air, 1.0 ml/min
for 2 h. Aliquots of the incubated homogenate (200 ml) were then
passed through an 1 ml Amprep CBA cation-exchange column for
determination of L-citrulline by high performance liquid chroma-
tography (HPLC). The method has been described in detail [18].
Since L-citrulline and NO are generated in equimolar amounts, and
since L-citrulline is stable whereas NO is not, L-citrulline is the
preferred parameter when measuring NO production. Protein
concentration was determined according to Bradford [37] on
samples from the original homogenate.
Immunofluorescence and confocal microscopy
Culturing of the freshly isolated islets (24 h) in the presence of
different agents were performed as stated above for the assay of
islet NOS activities. An aliquot of the medium was removed for
determination of insulin. The islets were then washed (3 times) and
fixed with 4% formaldehyde, permeabilized with 5% Triton X-
100, and unspecific sites were blocked with 5% Normal Donkey
Serum (Jackson Immunoresearch Laboratories Inc, West Grove,
PA). iNOS was detected with a rabbit-raised polyclonal anti-iNOS
antibody (StressGen Biotechnologies Corp, Victoria, BC, Canada)
(1:100) in combination with Cy2-conjugated anti-rabbit IgG
(Jackson Immunoresearch Laboratories Inc, West Grove, PA)
(1:150). For staining of insulin, islets were incubated with a guinea
pig-raised anti-insulin antibody (Eurodiagnostica, Malmo ¨, Swe-
den) (1:1000) followed by an incubation with a Cy5-conjugated
anti-guinea pig IgG antibody (Jackson Immunoresearch Labora-
tories Inc, West Grove, PA) (1:150). For scoring of iNOS positive
cells in islets multiple fields for each section were analysed under
blind conditions. The mean fluorescence intensity of cellular iNOS
was quantified using Zeiss LSM 5 analysis software. The
methodology for detection of mouse GPR40 has recently been
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tion with Cy2-conjugated anti-mouse IgG (1:150) were used. The
receptor specific antibody was raised in rabbit against the C-
terminal peptide: NH2-CVTRTQRGTIQK-COOH. The fluo-
rescence was visualized with a Zeiss LSM510 confocal microscope
by sequentially scanning at (excitation/emission) 488/505–
530 nm (Cy2) and 633/.650 nm (Cy5).
Cell culture and transfection
A subclone of the MIN6 cell line, MIN6c4, was grown in
Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax-1
(Invitrogen, Paisley, UK) supplemented with 15% heat-inactivated
FBS (Invitrogen), 60 mM b-mercaptoethanol, 50 U/ml penicillin,
and 50 mg/ml streptomycin. HEK293 cells were grown in DMEM
with Glutamax-1 supplemented with 3% FBS, 50 units/ml penicillin
and 50 mg/ml streptomycin. All cells were maintained in a 37uC
incubator with 7% CO2. The mouse GPR40 ORF (Genbank
accession number AB095745) was amplified with PCR (forward
primer, 59 GCCAAGCTTACCATGGACCTGCCCCCACAGC-
TCTCCTTCG 39; reverse primer, 59 GGCGAATTCCTACT-
TCTGAATTGTTCCTCTTTGAGTC 39), subcloned into the
pEAK12 expression vector (Edge BioSystems, Gaithersburg, MD),
and then transfected into HEK293 cells using Lipofectamine 2000
(Invitrogen),according to themanufacturer’sinstructions.Totaltime
of transfection was 6 h and the cells were assayed 48 h later.
PI hydrolysis
Receptor activation by FFA was assayed in the HEK293 and
MIN6c4 cells by measuring hydrolysis of phosphatidyl inositol (PI)
[38]. Briefly, MIN6c4 cells (approximately 100000 cells per well)
were pre-loaded with myo-[3H]inositol (Perkin Elmer, Boston,
MA) for 16–20 h and then thoroughly washed and incubated in
the KRB-buffer at 8.3 mmol/l glucose in the absence or presence
of palmitate (1 mmol/l)6ROZ (at different concentrations) for
30 min. After the incubation the cells were lysed with formic acid
on ice and the inositol phosphates were isolated using anion
exchange chromatography. The PI hydrolysis were expressed as PI
hydrolysis per well. The coefficient of variation (interassay
differences) was 7% for MIN6c4 cells.
Antisense intervention
Isolated islets (250 islets/vial) were incubated for 30 min with
palmitate (1 mmol/l) in KRB solution. After washing islets were
then cultured for 48 h in the absence or presence of 1.4 mmol/l of
M40 morpholino oligonucleotide. At day 2 (after 24 h culture)
palmitate (1 mmol/l) was added to the culture medium and the
islets were cultured for an additional period of 24 h. A nonspecific
random-sequence morpholino was used as control [5]. The
morpholino oligonucleotide was loaded into the islets using the
Gene-Tools special delivery system according to the manufactur-
ers instructions.
Determination of insulin
Insulin secretion and insulin content of the islets were
determined by radioimmunoassay [39].
Statistics
Results were expressed as means6s.e.m. The level of signifi-
cance for the difference between sets of data was assessed using
Student’s unpaired t-test or analysis of variance followed by
Tukey-Kramer’s test whenever appropriate. P,0.05 was consid-
ered statistically significant.
Acknowledgments
The technical assistance of Britt-Marie Nilsson is gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: AS. Performed the experiments:
SM BO EF. Analyzed the data: AS SM BO IL JG. Contributed reagents/
materials/analysis tools: AS SM. Wrote the paper: AS.
References
1. Poitout V, Robertson RP (2002) Minireview: Secondary beta-cell failure in type
2 diabetes–a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:
339–342.
2. McGarry JD, Dobbins RL (1999) Fatty acids, lipotoxicity and insulin secretion.
Diabetologia 42: 128–138.
3. Yaney GC, Corkey BE (2003) Fatty acid metabolism and insulin secretion in
pancreatic beta cells. Diabetologia 46: 1297–1312.
4. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. (2003) Free fatty
acids regulate insulin secretion from pancreatic beta cells through GPR40.
Nature 422: 173–176.
5. Salehi A, Flodgren E, Nilsson NE, Jimenez-Feltstrom J, Miyazaki J, et al. (2005)
Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-
stimulated insulin secretion. Cell Tissue Res 322: 207–215.
6. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H (2005) The
FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired
glucose homeostasis in mouse. Cell Metab 1: 245–258.
7. Gottlicher M, Widmark E, Li Q, Gustafsson JA (1992) Fatty acids activate a
chimera of the clofibric acid-activated receptor and the glucocorticoid receptor.
Proc Natl Acad Sci U S A 89: 4653–4657.
8. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, et al. (2004)
Rosiglitazone prevents the impairment of human islet function induced by fatty
acids: evidence for a role of PPARgamma2 in the modulation of insulin
secretion. Am J Physiol Endocrinol Metab 286: E560–567.
9. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, et al. (2007)
Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
Am J Physiol Endocrinol Metab 292: E871–883.
10. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest
116: 1802–1812.
11. Salehi A, Ekelund M, Henningsson R, Lundquist I (2001) Total parenteral
nutrition modulates hormone release by stimulating expression and activity of
inducible nitric oxide synthase in rat pancreatic islets. Endocrine 16: 97–104.
12. Salehi A, Ekelund M, Lundquist I (2003) Total parenteral nutrition-stimulated
activity of inducible nitric oxide synthase in rat pancreatic islets is suppressed by
glucagon-like peptide-1. Horm Metab Res 35: 48–54.
13. Qader SS, Jimenez-Feltstrom J, Ekelund M, Lundquist I, Salehi A (2007)
Expression of islet inducible nitric oxide synthase and inhibition of glucose-
stimulated insulin release after long-term lipid infusion in the rat is counteracted
by PACAP27. Am J Physiol Endocrinol Metab 292: E1447–1455.
14. Salehi A, Carlberg M, Henningson R, Lundquist I (1996) Islet constitutive nitric
oxide synthase: biochemical determination and regulatory function. Am J Physiol
270: C1634–1641.
15. Tsuura Y, Ishida H, Shinomura T, Nishimura M, Seino Y (1998) Endogenous
nitric oxide inhibits glucose-induced insulin secretion by suppression of
phosphofructokinase activity in pancreatic islets. Biochem Biophys Res
Commun 252: 34–38.
16. Takamura T, Kato I, Kimura N, Nakazawa T, Yonekura H, et al. (1998)
Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta
cells develop insulin-dependent diabetes without insulitis. J Biol Chem 273:
2493–2496.
17. Akesson B, Henningsson R, Salehi A, Lundquist I (1999) Islet constitutive nitric
oxide synthase and glucose regulation of insulin release in mice. J Endocrinol
163: 39–48.
18. Henningsson R, Salehi A, Lundquist I (2002) Role of nitric oxide synthase
isoforms in glucose-stimulated insulin release. Am J Physiol Cell Physiol 283:
C296–304.
19. Jimenez-Feltstrom J, Lundquist I, Obermuller S, Salehi A (2004) Insulin
feedback actions: complex effects involving isoforms of islet nitric oxide synthase.
Regul Pept 122: 109–118.
20. Jimenez-Feltstrom J, Lundquist I, Salehi A (2005) Glucose stimulates the
expression and activities of nitric oxide synthases in incubated rat islets: an effect
counteracted by GLP-1 through the cyclic AMP/PKA pathway. Cell Tissue Res
319: 221–230.
FFA, GPR40 and Insulin Release
PLoS ONE | www.plosone.org 9 May 2008 | Volume 3 | Issue 5 | e218221. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B (2003) A human cell
surface receptor activated by free fatty acids and thiazolidinedione drugs.
Biochem Biophys Res Commun 301: 406–410.
22. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. (2003)
The orphan G protein-coupled receptor GPR40 is activated by medium and
long chain fatty acids. J Biol Chem 278: 11303–11311.
23. Lajoix AD, Reggio H, Chardes T, Peraldi-Roux S, Tribillac F, et al. (2001) A
neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells
controls insulin secretion. Diabetes 50: 1311–1323.
24. Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, et al. (2001)
Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the
endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A 98:
10845–10850.
25. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M (2006)
Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 55 Suppl 2:
S16–23.
26. Yang C, Chang TJ, Chang JC, Liu MW, Tai TY, et al. (2001) Rosiglitazone
(BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-
kinase pathway. Diabetes 50: 2598–2602.
27. Shimabukuro M, Zhou YT, Lee Y, Unger RH (1998) Troglitazone lowers islet
fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273:
3547–3550.
28. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, et al. (2007) Beta-
cell ABCA1 influences insulin secretion, glucose homeostasis and response to
thiazolidinedione treatment. Nat Med 13: 340–347.
29. Yoshikawa H, Ma Z, Bjorklund A, Grill V (2004) Short-term intermittent
exposure to diazoxide improves functional performance of beta-cells in a high-
glucose environment. Am J Physiol Endocrinol Metab 287: E1202–1208.
30. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta
cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:
2498–2502.
31. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG (2001) Inverse
relationship between cytotoxicity of free fatty acids in pancreatic islet cells and
cellular triglyceride accumulation. Diabetes 50: 1771–1777.
32. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH (2001)
Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell
Biol 3: 193–197.
33. Wang X, Zhou L, Shao L, Qian L, Fu X, et al. (2007) Troglitazone acutely
activates AMP-activated protein kinase and inhibits insulin secretion from beta
cells. Life Sci 81: 160–165.
34. Cnop M, Hannaert JC, Pipeleers DG (2002) Troglitazone does not protect rat
pancreatic beta cells against free fatty acid-induced cytotoxicity. Biochem
Pharmacol 63: 1281–1285.
35. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, et al. (2007) GPR40 is
necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo.
Diabetes 56: 1087–1094.
36. Olofsson CS, Salehi A, Holm C, Rorsman P (2004) Palmitate increases L-type
Ca2+ currents and the size of the readily releasable granule pool in mouse
pancreatic beta-cells. J Physiol 557: 935–948.
37. Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem 72: 248–254.
38. Kang DS, Leeb-Lundberg LM (2002) Negative and positive regulatory epitopes
in the C-terminal domains of the human B1 and B2 bradykinin receptor
subtypes determine receptor coupling efficacy to G(q/11)-mediated [correction
of G(9/11)-mediated] phospholipase Cbeta activity. Mol Pharmacol 62:
281–288.
39. Heding L (1966) A simplified insulin radioimmunoassay method. Labelled
proteins in tracer studies. Donato L. MG, Sirchis J, eds. Brussels: Euratom. pp
345–350.
FFA, GPR40 and Insulin Release
PLoS ONE | www.plosone.org 10 May 2008 | Volume 3 | Issue 5 | e2182